Disclosure dos and don’ts
A piece in Lawyers Weekly by Jeremy de Beer laments the situation regarding patent disclosure. De Beer cites the uncertainty created by the Sanofi and AZT cases of the Supremes and the high bar for disclosure in the recent trial decision in Ratiopharm and concludes, “in the absence of an up-to-date prescription from the Supreme Court on the specifics of patent disclosure, Canadians are being delivered unhealthy doses of confusion.”
